[Selective cyclooxygenase-2 inhibitors and the digestive tract].
The use of non steroidal anti-inflammatory drugs (NSAIDs) is tempered by the development of side effects primarily in the gastro-intestinal tract. These effects result mainly from inhibition of the enzyme cyclo-oxygenase (COX)-1. Two NSAIDs (celecoxib and rofecoxib) COX-2 specific inhibitors had considerably lower ulcerogenic rates and lower serious gastro-intestinal side effects when compared with other NSAIDs used in rheumatoid arthritis and osteoarthritis. However, the exact place of COX-2 specific inhibitors remain to be determined as compared with the association of other NSAIDs and proton-pump inhibitors in the elderly. The efficacy of COX-2 specific inhibitors in digestive tumors is still unclear.
Chaabouni
Hatem
H
Amouri
Ali
A
Cheikh
Imed
I
Kchaou
Mehdi
M
Ouerghi
Hajer
H
Ben Mami
Nabyl
N
Ben Ammar
Ahmed
A
D000367:Age Factors; D000894:Anti-Inflammatory Agents, Non-Steroidal / Q000009:adverse effects; D000068579:Celecoxib; D016861:Cyclooxygenase Inhibitors / Q000009:adverse effects / Q000494:pharmacology*; D004064:Digestive System / Q000187:drug effects* / Q000473:pathology*; D005770:Gastrointestinal Neoplasms / Q000139:chemically induced; D006801:Humans; D007783:Lactones / Q000009:adverse effects / Q000494:pharmacology*; D011720:Pyrazoles; D013276:Stomach Ulcer / Q000139:chemically induced; D013449:Sulfonamides / Q000009:adverse effects / Q000494:pharmacology*; D013450:Sulfones
D000894:Anti-Inflammatory Agents, Non-Steroidal; D016861:Cyclooxygenase Inhibitors; D007783:Lactones; D011720:Pyrazoles; D013449:Sulfonamides; D013450:Sulfones; C116926:rofecoxib; D000068579:Celecoxib
Inhibiteurs selectifs de la cyclo-oxygenase-2 et tube digestif.